# University of Cape Town researchers are part of a groundbreaking global clinical trial using CRISPR-Cas9, a gene-editing technology to treat hereditary angio-edema. HAE is a rare and life-threatening genetic disorder that causes recurrent episodes of swelling in the limbs, face, intestinal tract, and airway. According to the Allergy Foundation of South Africa, early results show promising reductions in angio-edema attacks. UCT’s involvement marks a major step for gene therapy in South Africa and positions the continent at the forefront of global gene-editing innovation.
UCT joins global gene-editing trial to treat rare genetic disorder